Regulatory Insights

31. Improving Clinical Trial Label Translation Through Centralized Reuse And Control 8/10/2026

    Eliminate workflow inefficiencies and regulatory risk in global trials with a centralized translation framework and validated phrase library for consistent, cost-effective execution.

32. 7 Practical Implications Of ICH E6(R3) For Early-Phase Trial Design 8/10/2026

    A risk-based quality approach can enhance participant protection, data integrity, and development success through focused oversight, strong governance, and clear documentation.

33. Speed Kills: When Timelines Trump Science In Neuropsychiatric Trials 8/4/2026

    This Bold Conversation brings together experts helping to define the next chapter of psychedelic clinical research to unpack lessons from recent regulatory reviews and explore what clinical teams need now.

34. Accelerating Psychedelic Therapeutics: A Regulatory Inflection Point In Mental Health 8/4/2026

    A 2026 executive order is fast-tracking psychedelic therapies for depression, PTSD, and addiction. Understand what this regulatory shift means for your next clinical trial.

35. FDA Approvals Of Two Novel Agents For The Acute Treatment Of Migraine 7/31/2026

    Parallel trials, compressed timelines, thousands of patients. Discover the data oversight strategies that kept two programs on track to approval

36. The FDA Just Rewrote The Rules For Clinical Trials. Here's What It Means For RTSM. 7/30/2026

    Learn how evolving trial designs are changing RTSM requirements and driving demand for greater flexibility, traceability, and execution quality.

37. Real-Time Trials Need Real-Time Data You Can Trust 7/30/2026

    The FDA just kicked off real-time clinical trials with AstraZeneca and Amgen. But speed means nothing if the underlying data is inconsistent.

38. The Renaissance Of Psychedelic Research: History, Protocols, And Forward Trajectories 7/30/2026

    Discover how clinical trial protocols are evolving to address unblinding, therapeutic support variables, and regulatory standards in modern psychedelic research.

39. Making Early Decisions In Psychiatric Drug Development 7/30/2026

    Quantitative PD measures provide objective evidence of target engagement, support dose selection, strengthen early go/no-go decisions, and help reduce development risk in psychiatric

40. EU Clinical Trial Regulation Timelines: Shorter Than Many Expect 7/30/2026

    The EU CTR rewards early planning. Strong documentation, regulatory readiness, and aligned partners can help accelerate approvals and reduce delays.